| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.0934 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.0968 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.1098 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.1298 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.1305 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.1592 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.1675 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.1974 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.2001 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.2092 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.2238 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.2528 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.2545 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.3089 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.3285 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.3583 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.3849 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.3897 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.3906 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.3959 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.4096 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.4405 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.4550 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.4673 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.4906 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.4978 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5073 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5091 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5097 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5133 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5159 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5192 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5226 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5321 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5344 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5632 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5689 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5701 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5756 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5809 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5903 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5978 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.5983 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6026 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6048 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6124 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6137 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6177 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6231 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6333 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6475 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6543 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6604 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6715 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6791 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6807 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6838 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.6968 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7083 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7204 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7382 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7382 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7405 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7440 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7566 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7756 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7880 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7912 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.7949 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8145 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8235 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8245 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8277 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8319 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8505 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8590 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8615 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8616 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8753 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8804 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.8852 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9147 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9294 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9337 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9339 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9492 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9554 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9619 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9660 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9715 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9720 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 0.9846 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0000 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0020 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0065 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0093 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0113 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0154 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0158 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0217 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0224 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0264 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0404 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0405 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0731 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0743 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0746 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0801 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0872 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0899 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0909 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0990 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.0996 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1007 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1018 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1036 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1061 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1111 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1234 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1344 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1543 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1555 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1841 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1867 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1951 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.1953 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2070 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2170 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2234 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2234 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2366 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2460 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2537 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2580 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2639 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2732 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2854 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.2873 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.3301 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.3430 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.3446 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.3686 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.3904 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.4017 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.4278 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.4460 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.4682 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5161 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5227 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5284 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5295 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5320 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5438 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5467 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5468 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5619 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5748 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5906 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5940 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5960 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.5992 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.6019 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.6199 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.6259 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.6295 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.6989 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.7201 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.7242 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.7260 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.8432 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.9315 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 1.9622 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.0315 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.0385 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.0583 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.0729 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.1063 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.1550 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.2392 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.2603 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.3184 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.3210 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.6385 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.6938 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 2.8586 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | linoleate (18:2n6) | 3.0098 | scaled units | Low-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|